300485 赛升药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)1.533-2.0273.0236.18713.300
总资产报酬率 ROA (%)1.449-1.9202.8625.87412.585
投入资产回报率 ROIC (%)1.489-1.9702.9366.06413.172

边际利润分析
销售毛利率 (%)65.55666.28270.42676.63882.668
营业利润率 (%)19.198-19.92325.54434.66641.777
息税前利润/营业总收入 (%)18.889-20.47025.41434.60240.704
净利润/营业总收入 (%)15.731-18.45820.23027.58837.603

收益指标分析
经营活动净收益/利润总额(%)10.273-30.401-33.6269.43024.096
价值变动净收益/利润总额(%)107.942129.395131.03383.30972.533
营业外收支净额/利润总额(%)-0.0900.7090.349-0.0080.006

偿债能力分析
流动比率 (X)21.79620.86026.30017.62117.298
速动比率 (X)20.90619.86824.21916.43215.907
资产负债率 (%)4.7514.6874.2684.4023.485
带息债务/全部投入资本 (%)0.6870.1080.1720.2530.374
股东权益/带息债务 (%)14,089.65090,494.81556,495.61338,469.30426,389.748
股东权益/负债合计 (%)1,990.2742,016.5132,222.3702,147.6772,737.166
利息保障倍数 (X)-64.83150.480-115.483-563.178-37.840

营运能力分析
应收账款周转天数 (天)40.49840.74446.43140.96435.355
存货周转天数 (天)195.664241.526250.518222.522278.408